lancet-header

Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.

Comparison of Excess Deaths and Laboratory-Confirmed COVID-19 Deaths During a Large Omicron Epidemic in 2022 in Hong Kong

26 Pages Posted: 7 Jul 2024

See all articles by Hualei Xin

Hualei Xin

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control

Alexandra Law

The University of Hong Kong

Justin Cheung

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control

Yun Lin

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control

Peng Wu

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control

Zhongjie Li

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC)

Benjamin J. Cowling

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control

Weizhong Yang

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - School of Population Medicine and Public Health

Jessica Y. Wong

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control

More...

Abstract

Background: Using a local elimination strategy, Hong Kong was able to minimize COVID-19 mortality in 2020 and 2021, but a large epidemic caused by the Omicron variant occurred in 2022. We aimed to estimate the overall, age-, sex-, epidemic period- and cause-specific excess mortality in 2022 in Hong Kong and compared excess mortality to laboratory-confirmed COVID-19 mortality. 

Methods: Negative binomial regression analysis was used to model time series of weekly all-cause and cause-specific deaths from 2010 to 2021 to predict the weekly number of deaths in 2022 against counterfactual baselines projected from the trends in the absence of a pandemic. The estimated excess deaths were compared with laboratory-confirmed COVID-19 deaths overall and by age and epidemic period. 

Findings: We estimated that there were 13,500 (95% CI: 13,400-13,600) excess deaths in 2022, which was slightly higher than the 12,228 deaths recorded with laboratory-confirmed COVID-19, with the majority of the excess deaths and laboratory-confirmed deaths occurring among older adults. The increased number of excess deaths over laboratory-confirmed COVID-19 deaths was most substantial from February to April 2022 (a difference of 847 deaths), when the largest Omicron wave peaked. Most of the excess deaths (78%) were from respiratory causes, while 10% were from cardiovascular causes. A slight reduction in malignant neoplasm mortality was identified among older adults in 2022. 

Interpretation: A substantial increase in population mortality was identified in 2022 in Hong Kong, slightly larger than the laboratory-confirmed COVID-19 deaths. Apart from the possibility of underdiagnosis, excess deaths might also be attributed to the overload of healthcare resources during the pandemic. Deaths from COVID-19 may have displaced some deaths that would otherwise have occurred due to other causes although we did not find evidence of substantial mortality displacement. 

Funding: This project was financially supported by the Health and Medical Research Fund from the Health Bureau of the Government of the Hong Kong Special Administrative Region (grant no: CID-HKU2-14), and by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. T11-705/21-N).

Declaration of Interest: B.J.C. has consulted for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. All other authors report no potential conflicts of interest.

Ethical Approval: Our study received ethical approval from the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.

Keywords: COVID-19, Excess mortality, Laboratory-confirmed COVID-19 mortality, Omicron, Elimination

Suggested Citation

Xin, Hualei and Law, Alexandra and Cheung, Justin and Lin, Yun and Wu, Peng and Li, Zhongjie and Cowling, Benjamin J. and Yang, Weizhong and Wong, Jessica Y., Comparison of Excess Deaths and Laboratory-Confirmed COVID-19 Deaths During a Large Omicron Epidemic in 2022 in Hong Kong. Available at SSRN: https://ssrn.com/abstract=4885935 or http://dx.doi.org/10.2139/ssrn.4885935

Hualei Xin

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control ( email )

Alexandra Law

The University of Hong Kong ( email )

Justin Cheung

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control ( email )

Hong Kong
China

Yun Lin

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control ( email )

Hong Kong
China

Peng Wu (Contact Author)

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control ( email )

Hong Kong
China

Zhongjie Li

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) ( email )

Benjamin J. Cowling

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control ( email )

7 Sassoon Road
Hong Kong
China
+852 3917 6711 (Phone)

Weizhong Yang

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - School of Population Medicine and Public Health ( email )

China

Jessica Y. Wong

The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control ( email )

Hong Kong
China

Click here to go to TheLancet.com

Paper statistics

Downloads
41
Abstract Views
171
PlumX Metrics